CagriSema

News

Under pressure, Novo lays out blockbuster launch plans

Novo has revealed a plan to launch five or more blockbusters between now and 2030 that it hopes will grow annual revenues by around $23bn.

News

Novo fails to shrug off investor concern at Q2 update

Novo Nordisk's better-than-expected second-quarter revenues can't outweigh worries about oral Wegovy growth and another CagriSema disappointment.

News

US judge says Novo Nordisk must face lawsuit over CagriSema

A US judge has ruled that Novo Nordisk must face a lawsuit claiming it defrauded investors with misleading statements about a pivotal CagriSema study.

News

ADA: Lilly's weight-loss reveal, and wannabes display wares

Lilly reveals more details of its retatrutide obesity and diabetes studies, plus trial updates from Zealand/Roche, Pfizer, Novo Nordisk, and Sciwind.

News

After CagriSema blow, Novo reveals data for obesity 'triple'

Novo Nordisk's triple-action obesity therapy UBT251, licensed in a $2bn deal last year, achieved almost 20% weight loss in a mid-stage trial.

News

Cartoon graphic of a woman with glasses holding thought bubbles in the palm of either hand, one with a check and one with a cross

Head-to-head trial dents Novo Nordisk's obesity hopes

Novo Nordisk slumps as its two-drug combination for weight loss, CagriSema, performs less well than Eli Lilly's rival Zepbound in a comparative trial.

Under pressure, Novo lays out blockbuster launch plans

Novo fails to shrug off investor concern at Q2 update

US judge says Novo Nordisk must face lawsuit over CagriSema

ADA: Lilly's weight-loss reveal, and wannabes display wares

After CagriSema blow, Novo reveals data for obesity 'triple'

Head-to-head trial dents Novo Nordisk's obesity hopes

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

CagriSema

Editor's Picks